ArticleOncoimmunology2022
Homologous recombination repair deficient prostate cancer represents an immunologically distinct subtype.
Sandra van Wilpe et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
8 papers cite it
this papercites it